| Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards. | |
| | |
MedLine Citation:
|
PMID: 15025745 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIMS: To assess the potential for interactions involving cytochromes P450 2D6 (CYP2D6) and 3A4 (CYP3A4) between drugs prescribed in a city in-patient psychiatric service. METHODS: Prescription information was obtained from all 236 patients in general adult wards and all 87 patients in functional elderly wards under a city psychiatric service. The frequencies with which combinations of drugs expected to interact via CYP2D6 or CYP3A4 were documented and compared between these two settings. RESULTS: All 2089 drug prescriptions, of which 1237 (59%) were administered, were analyzed. One hundred and seventy-two patients (73%) on adult wards and 59 (68%) on functional elderly wards were prescribed at least one drug metabolized by and/or inhibiting CYP2D6, the difference being nonsignificant (95% confidence interval on the difference -6.3%, 16.4%). Anticipated interactions from 62/82 CYP2D6-related combinations prescribed on adult wards (27/100 patients) and 19/30 prescribed to elderly patients (22/100 patients) were judged to be clinically important or potentially clinically important. The proportion of patients on functional elderly wards prescribed at least one drug interacting with CYP3A4 (87%) was significantly greater than that for patients on adult wards (57%, P < 0.001). The frequency of interactions involving CYP3A4 was significantly greater on functional elderly than adult wards (43/100 vs 22/100 patients, P < 0.025, 95% confidence interval on the difference 4, 38/100). CONCLUSIONS: Our findings confirm extensive polypharmacy on general adult psychiatric and functional elderly psychiatric wards. A substantial proportion of patients were receiving combinations of drugs that interact with CYP2D6 and/or CYP3A4, many of which are known to produce clinically important interactions. Doctors practising in old age psychiatry should be aware that patients on functional elderly wards are at increased risk of clinically important CYP3A4 interactions. Psychiatrists should consider the pharmacokinetic implications of drugs prescribed for use 'as needed', because of the potential for unpredictable interactions. |
| | |
Authors:
|
S J C Davies; S Eayrs; P Pratt; M S Lennard |
Related Documents
:
|
21030355 - New drug update: 2010. 4047285 - Evidence for an increased rate of choline efflux across erythrocyte membranes in alzhei... 8130925 - Drug prescribing for the elderly. 20809665 - Risk of potential drug-drug interactions among brazilian elderly: a population-based, c... 7791255 - Incidence of adverse drug events and potential adverse drug events. implications for pr... 12678835 - Oxazolidinone antibacterial agents: a critical review. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: British journal of clinical pharmacology Volume: 57 ISSN: 0306-5251 ISO Abbreviation: Br J Clin Pharmacol Publication Date: 2004 Apr |
Date Detail:
|
Created Date: 2004-03-17 Completed Date: 2004-07-12 Revised Date: 2009-11-18 |
Medline Journal Info:
|
Nlm Unique ID: 7503323 Medline TA: Br J Clin Pharmacol Country: England |
Other Details:
|
Languages: eng Pagination: 464-72 Citation Subset: IM |
Affiliation:
|
Academic Unit of Molecular and Clinical Pharmacology, University of Sheffield, Royal Hallamshire Hospital, Sheffield S10 2JF, UK. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Cytochrome P-450 CYP2D6 Cytochrome P-450 CYP3A Cytochrome P-450 Enzyme System Drug Combinations Drug Interactions Hospitalization Hospitals, Psychiatric Humans Medical Audit Mental Disorders / drug therapy* Middle Aged |
| Chemical | |
Reg. No./Substance:
|
0/Drug Combinations; 9035-51-2/Cytochrome P-450 Enzyme System; EC 1.14.13.67/CYP3A4 protein, human; EC 1.14.14.1/CYP3A protein, human; EC 1.14.14.1/Cytochrome P-450 CYP2D6; EC 1.14.14.1/Cytochrome P-450 CYP3A |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Clinical inhibition of CYP2D6-catalysed metabolism by the antianginal agent perhexiline.
Next Document: Database analyses for the prediction of in vivo drug-drug interactions from in vitro data.